Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence

Abstract

LRG1 could serve as a potential target and as a biomarker to identify patients with high risk for disease recurrence, and consequently benefit from additional therapies and intensive follow-up.